Virogin Biotech
BC - Richmond
BiotechnologyFocus: Oncolytic Virotherapy
Virogin Biotech is a life sciences company focused on Oncolytic Virotherapy.
Oncology
Employees
51-200
Open Jobs
0
Pipeline & Clinical Trials
VG2025
Solid TumorClinical Trials (1)
NCT05266612Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Phase 1Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Advanced Malignant Solid TumorClinical Trials (1)
NCT05477849A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Phase 1Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Advanced Malignant Solid TumorClinical Trials (1)
NCT04758897Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors
Phase 1Placebo
SARS-CoV-2 InfectionClinical Trials (1)
NCT06113744A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
Phase 1Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Primary Liver CancerClinical Trials (1)
NCT04806464Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
Phase 1Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Advanced Malignant Solid TumorClinical Trials (1)
NCT07262164A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
Phase 1Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Metastatic Gastric CancerClinical Trials (1)
NCT06008925Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT07357220A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
Phase 1/2Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Primary Hepatocellular CarcinomaClinical Trials (1)
NCT06124001Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
Phase 1/2COVID-19 mRNA Vaccine
SARS-CoV-2 InfectionClinical Trials (1)
NCT06113731A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
Phase 2Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Advanced Intrahepatic CholangiocarcinomaClinical Trials (1)
NCT06746480Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
Phase 2Phase 2
Clinical Trials (1)
NCT05223816An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Phase 2Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
SarcomaClinical Trials (1)
NCT06126510Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2024
Portfolio: 13 clinical trials